ReP USP - Resultado da busca

Artigo de periodico
In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology (2014)
Caso, Francesca; Mandelli, Maria Luisa; Henry, Maya; Gesierich, Benno; Bettcher, Brianne M.; Ogar, Jennifer; Filippi, Massimo; Comi, Giancarlo; Magnani, Giuseppe; Sidhu, Manu; Trojanowski, John Q.; Huang, Eric J.; Grinberg, Lea T.; Miller, Bruce L.; Dronkers, Nina; Seeley, William W.; Gorno-Tempini, Maria Luisa
Fonte: Neurology. Unidade: FM
Assuntos: COGNIÇÃO (ANORMALIDADES), AFASIA PROGRESSIVA, AGRAMATISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASO, Francesca et al. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. Neurology, v. 82, n. 3, p. 239-247, 2014Tradução . . Disponível em: https://doi.org/10.1212/WNL.0000000000000031. Acesso em: 02 nov. 2025.
APA
Caso, F., Mandelli, M. L., Henry, M., Gesierich, B., Bettcher, B. M., Ogar, J., et al. (2014). In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. Neurology, 82( 3), 239-247. doi:10.1212/WNL.0000000000000031
NLM
Caso F, Mandelli ML, Henry M, Gesierich B, Bettcher BM, Ogar J, Filippi M, Comi G, Magnani G, Sidhu M, Trojanowski JQ, Huang EJ, Grinberg LT, Miller BL, Dronkers N, Seeley WW, Gorno-Tempini ML. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology [Internet]. Neurology. 2014 ; 82( 3): 239-247.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1212/WNL.0000000000000031
Vancouver
Caso F, Mandelli ML, Henry M, Gesierich B, Bettcher BM, Ogar J, Filippi M, Comi G, Magnani G, Sidhu M, Trojanowski JQ, Huang EJ, Grinberg LT, Miller BL, Dronkers N, Seeley WW, Gorno-Tempini ML. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology [Internet]. Neurology. 2014 ; 82( 3): 239-247.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1212/WNL.0000000000000031
Artigo de periodico
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study (2011)
Khatri, Bhupendra; Barkhof, Frederik; Comi, Giancarlo; Hartung, Hans-Peter; Kappos, Ludwig; Montalban, Xavier; Pelletier, Jean; Stites, Tracy; Wu, Stacy; Holdbrook, Fred; Zhang-Auberson, Lixin; Francis, Gordon; Cohen, Jeffrey A.; Barreira, Amilton Antunes
Fonte: The Lancet Neurology. Unidade: FMRP
Assuntos: ESCLEROSE MÚLTIPLA (TRATAMENTO), FÁRMACOS IMUNOSSUPRESSORES, ESTUDOS RANDOMIZADOS, PACIENTES (AVALIAÇÃO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KHATRI, Bhupendra et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology, v. 10, n. 6, p. 520-529, 2011Tradução . . Disponível em: https://doi.org/10.1016/S1474-4422(11)70099-0. Acesso em: 02 nov. 2025.
APA
Khatri, B., Barkhof, F., Comi, G., Hartung, H. -P., Kappos, L., Montalban, X., et al. (2011). Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology, 10( 6), 520-529. doi:10.1016/S1474-4422(11)70099-0
NLM
Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, Barreira AA. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study [Internet]. The Lancet Neurology. 2011 ; 10( 6): 520-529.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1474-4422(11)70099-0
Vancouver
Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, Barreira AA. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study [Internet]. The Lancet Neurology. 2011 ; 10( 6): 520-529.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1474-4422(11)70099-0
Artigo de periodico
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis (2010)
Cohen, Jeffrey A.; Barkhof, Frederik; Comi, Giancarlo; Hartung, Hans-Peter; Khatri, Bhupendra O.; Montalban, Xavier; Pelletier, Jean; Capra, Ruggero; Gallo, Paolo; Izquierdo, Guillermo; Tiel-Wilck, Klaus; Vera, Ana de; Jin, James; Stites, Tracy; Wu, Stacy; Aradhye, Shreeram; Kappos, Ludwig; Barreira, Amilton Antunes
Fonte: New England Journal of Medicine. Unidade: FMRP
Assuntos: DOENÇAS DO SISTEMA NERVOSO, FÁRMACOS IMUNOSSUPRESSORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COHEN, Jeffrey A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine, v. 362, n. 5, p. 402-415, 2010Tradução . . Acesso em: 02 nov. 2025.
APA
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H. -P., Khatri, B. O., Montalban, X., et al. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine, 362( 5), 402-415.
NLM
Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, Vera A de, Jin J, Stites T, Wu S, Aradhye S, Kappos L, Barreira AA. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine. 2010 ; 362( 5): 402-415.[citado 2025 nov. 02 ]
Vancouver
Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, Vera A de, Jin J, Stites T, Wu S, Aradhye S, Kappos L, Barreira AA. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine. 2010 ; 362( 5): 402-415.[citado 2025 nov. 02 ]

Unidades USP

ReP

Filtros

Autores

Assuntos

Indexado em

Afiliação dos autores externos não normalizada